Boston Scientific Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael F. Mahoney
- Full Time Employees
- 59,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 300 Boston Scientific Way Marlborough MA United States of America 01752-1234
- IPO Date
- May 19, 1992
- CIK
- 0000885725
- Website
- bostonscientific.com
- Similar Companies
- Business
- Boston Scientific Corporation (NYSE: BSX) develops, manufactures and markets innovative medical devices for a wide range of interventional medical specialties worldwide. The company operates through two primary reportable segments, MedSurg and Cardiovascular, encompassing eight core businesses: Cardiac Rhythm Management, Electrophysiology, Endoscopy, Interventional Cardiology Therapies, Neuromodulation, Peripheral Interventions, Urology and WATCHMAN; its product portfolio includes pacemakers, defibrillators (S-ICD, ICD), CRT-P devices, deep brain stimulation systems, radiofrequency ablation systems for pain management, renal denervation technologies, direct visualization systems, embolic protection and embolization devices, FFR and IVUS systems, guidewires, imaging systems, intragastric balloons, lasers for BPH and lithotripsy, plaque modification tools, retrieval devices, RF ablation systems, hemostasis needles, hepatopancreatobiliary stents, hydrogel spacers, infection prevention products, pelvic floor reconstruction devices, penile prostheses and single-use imaging systems. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company maintains commercial operations in over 127 countries, including the U.S., Europe, Middle East and Africa, Asia-Pacific, Latin America and Canada, serving approximately 44 million patients annually through healthcare professionals in fields such as interventional cardiology, endoscopy, neuromodulation, peripheral interventions and urology. In recent developments, Boston Scientific has pursued an aggressive acquisition strategy, including agreements to acquire Bolt Medical for up to $664 million to enhance its intravascular lithotripsy offerings for coronary and peripheral artery disease (expected close in first half of 2025), SoniVie Ltd. for up to $600 million to advance therapeutic intravascular ultrasound for renal denervation in hypertension treatment (expected close in first half of 2025), Elutia's BioEnvelope division to reduce complications in cardiac rhythm management devices, Anrei Medical for $182 million to bolster endoscopy solutions, Intera Oncology for interventional oncology in liver metastases, and Cortex; the company also completed its $3.7 billion acquisition of Axonics in November 2024 and received $2.6 million in state funding for a 52,000-square-foot manufacturing expansion at its Maple Grove, Minnesota campus to support WATCHMAN product growth, alongside launching approximately 100 new products in 2024.
Company News
Boston Scientific: $43 Finally Prices In A Bad 2026
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Boston Scientific Restores Key Operations After Cyberattack
Boston Scientific Corporation $BSX Shares Acquired by Concurrent Investment Advisors LLC
Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
Boston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead?
Stock Futures Mixed to Start Holiday-Shortened Week
Boston Scientific ‘Unlikely to Meet' Earnings Guidance After Cyberattack. Stock Falls.
Boston Scientific Won't Meet Guidance Due to Cyberattack
Boston Scientific says cyberattack likely to hurt 2026 sales, profit
AlphaGrep UK Ltd Makes New $978,000 Investment in Boston Scientific Corporation $BSX
Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?
B. Metzler seel. Sohn & Co. AG Has $14.24 Million Position in Boston Scientific Corporation $BSX
Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?
New Strong Sell Stocks for August 28th
Stock Market Today, Aug. 26: Boston Scientific Shares Fall 5% on Cybersecurity Incident and Product Recall